Hiki i nā poʻe maʻi maʻi maʻi umauma mua ke pale aku i ke kemoterapi

A HOLD Hoʻokuʻu ʻole 1 | eTurboNews | eTN

I loko o ke aʻo ʻana, ʻaʻohe pono o nā wahine postmenopausal me 1 a 3 mau nodes maikaʻi a me Recurrence Score® o 0 a 25 i ka pōmaikaʻi mai ka chemotherapy ma hope o ka median o ʻelima mau makahiki o ka hahai ʻana, ʻo ia hoʻi hiki iā lākou ke pale i nā hopena maikaʻi ʻole o ka mālama ʻana.

Ua hoʻolaha ʻo Exact Science Corp. i kēia lā ua paʻi ʻia ka ʻikepili mai ka Rx for Positive Node, Endocrine Responsive Breast Cancer, a i ʻole RxPONDER, hoʻokolokolo ma The New England Journal of Medicine.i ʻO ke aʻo ʻana, alakaʻi ʻia e ka SWOG Cancer Research Network kūʻokoʻa a kākoʻo ʻia e ka ʻO ka National Cancer Institute (NCI), i wehewehe maikaʻi i ka pōmaikaʻi o ka chemotherapy i ka wā mua, node-positive breast cancer maʻi me Oncotype DX Breast Recurrence Score® nā hualoaʻa o 0 a 25. Ua hōʻike ʻia nā hopena mua mai RxPONDER ma 2020 San Antonio Breast Cancer ʻO ka hui kūkākūkā (SABCS). Ua hōʻoia ʻia nā mea i ʻike ʻia ma kēia puke i loiloi ʻia e nā hoa.

ʻO ka mea nui, ʻaʻole i ʻike ʻia ka pōmaikaʻi o ka chemotherapy me ka nānā ʻole i ka nui o nā nodes i hoʻopilikia ʻia, ka pae tumo a i ʻole ka nui. I nā wahine premenopausal me 1 a 3 mau nodes maikaʻi, ua ʻike ʻia kahi pōmaikaʻi nui o ka chemotherapy.

Ma kahi o hoʻokahi hapakolu o nā maʻi i loaʻa i ka hormone receptor (HR) -positive, HER2-negative early breast cancer i loaʻa i kahi maʻi koko i laha i ko lākou mau lymph nodes. ʻO ka hapa nui o kēia mau maʻi i loaʻa i ka chemotherapyii i kēia manawa ʻoiai ma kahi o 85% o lākou i loaʻa nā hopena Recurrence Score o 0 a 25.

Ma muli o nā hualoaʻa RxPONDER, ua hōʻano hou ka National Comprehensive Cancer Network® (NCCN®) v i kāna mau alakaʻi no ka maʻi kanesa o ka umauma a ʻike i ka Oncotype DX Breast Recurrence Score hōʻike ʻo ia wale nō ka hoʻāʻo e hiki ke hoʻohana no ka wānana o ka pōmaikaʻi chemotherapy i ka umauma mua. ʻO nā maʻi maʻi maʻi maʻi me 1 a 3 mau puʻupuʻu lymph axillary maikaʻi, me nā micrometastases.vi ʻO ka hoʻāʻo Oncotype DX i kēia manawa ʻo ia wale nō ka hōʻike i koho ʻia ma ke ʻano he "makemake" me ka pae kiʻekiʻe o nā hōʻike no ka node-negative a me ka postmenopausal node-positive (1 a 3 mau nodes maikaʻi. ) nā maʻi. Eia kekahi, paipai ʻo NCCN e noʻonoʻo i ka hoʻāʻo e loiloi i ka prognosis i nā maʻi premenopausal node-positive nā moho no ka chemotherapy.

ʻO kekahi o nā hoʻokolohua lapaʻau nui loa i ka node-positive, HR-positive, HER2-negative early breast cancer, RxPONDER i kākau inoa ma mua o 5,000 wahine me ʻekolu mau nodes maikaʻi. Ua mālama ʻia ke aʻo ʻana o ka Phase III i koho ʻia ma 632 mau ʻāina ma ʻeiwa mau ʻāina - ʻo ʻAmelika Hui Pū ʻIa, Kanada, Mekikoka, Kolombia, ʻIlelani, Palani, Sepania, South Korea a me Saudi Arabia. ʻO nā wāhine me ka hopena o ka hoʻihoʻi hou ʻana o 0 a 25 ua hoʻopaʻa ʻia me ka lāʻau lapaʻau wale nō a i ʻole ka chemotherapy i ukali ʻia e ka hormone therapy. Ua hoʻopaʻa ʻia nā maʻi maʻi ma muli o kā lākou Recurrence Score result, menopausal status and type of lymph node surgery. Hoʻolālā ʻia nā loiloi hou aʻe a me nā mea maʻi hou e ka poʻe noiʻi SWOG.

No ka mea kākau

Avatar o Linda Hohnholz, hoʻoponopono eTN

ʻO Linda Hohnholz, ka mea hoʻoponopono eTN

Ua kākau a hoʻoponopono ʻo Linda Hohnholz i nā ʻatikala mai ka hoʻomaka ʻana o kāna ʻoihana hana. Ua hoʻohana ʻo ia i kēia kuko nui i loko o nā wahi e like me ke Kulanui ʻo Hawaii Pacific, ke Kulanui Chaminade, ke Keiki ʻImi PepeʻIke o Hawaiʻi, a ʻo TravelNewsGroup i kēia manawa.

kakau
E hoʻomaopopo i
malihini
0 Comments
Nā ʻōlelo Hoʻohui Kūʻai
E nānā i nā ʻōlelo āpau
0
E aloha nui i kou mau manaʻo, e ʻoluʻolu.x
()
x
Kaʻana like i...